Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a regulatory disclosure regarding equity plan transactions rather than a financial performance report.
Material Changes
The document details increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for specific directors and PDMRs. These increases resulted from the notional re-investment of dividends paid to shareholders on January 9, 2014. The transaction prices were 1597.50 pence per Ordinary Share and $52.84 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the vesting mechanics of the Performance Share Plan, noting that accrued notional dividends will be paid out based on the percentage of holdings that vest after the relevant measurement period.
Important Facts for Investors
- Transaction Type: Notional re-investment of dividends into the 2009 Performance Share Plan.
- Key Dates: Dividend paid on January 9, 2014; notification issued on January 16, 2014.
- Share Prices: Ordinary Shares at 1597.50 pence; ADSs at $52.84.
- Participants: Includes Sir Andrew Witty, Dr M M Slaoui, Mr S Dingemans, and 12 other directors/PDMRs.
- Financial Data: No operational or financial performance data is included in this specific filing.